Radiotherapy-Specific Chronic Pain Syndromes in the Cancer Population: An Evidence-Based Narrative Review
Abstract While radiation therapy is increasingly utilized in the treatment paradigm of many solid cancers, the chronic effects of radiation therapies are poorly characterized. Notably, understanding radiation-specific chronic pain syndromes is paramount given that the diagnosis and management of these conditions can serve to prevent long-standing functional impairments, optimize quality of life, and even allow for continued radiotherapy candidacy. These radiation-specific chronic pain phenomena include dermatitis, mucositis, enteritis, connective tissue fibrosis, lymphedema, and neuropathic pain syndromes. It is necessary to maintain a low threshold of suspicion for appropriately diagnosing these conditions as there exists a variance in when these symptoms arise after radiation. However, we present key epidemiological data delineating vulnerable cancer populations for each pain syndrome along with the available evidence for the management for each specific condition..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Advances in therapy - 38(2021), 3 vom: 11. Feb., Seite 1425-1446 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karri, Jay [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Cancer |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Healthcare Ltd. part of Springer Nature 2021 |
|---|
| doi: |
10.1007/s12325-021-01640-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2124170120 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2124170120 | ||
| 003 | DE-627 | ||
| 005 | 20230505084152.0 | ||
| 007 | tu | ||
| 008 | 230505s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-021-01640-x |2 doi | |
| 035 | |a (DE-627)OLC2124170120 | ||
| 035 | |a (DE-He213)s12325-021-01640-x-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.40$jPharmazie$jPharmazeutika |2 bkl | ||
| 100 | 1 | |a Karri, Jay |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radiotherapy-Specific Chronic Pain Syndromes in the Cancer Population: An Evidence-Based Narrative Review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Healthcare Ltd. part of Springer Nature 2021 | ||
| 520 | |a Abstract While radiation therapy is increasingly utilized in the treatment paradigm of many solid cancers, the chronic effects of radiation therapies are poorly characterized. Notably, understanding radiation-specific chronic pain syndromes is paramount given that the diagnosis and management of these conditions can serve to prevent long-standing functional impairments, optimize quality of life, and even allow for continued radiotherapy candidacy. These radiation-specific chronic pain phenomena include dermatitis, mucositis, enteritis, connective tissue fibrosis, lymphedema, and neuropathic pain syndromes. It is necessary to maintain a low threshold of suspicion for appropriately diagnosing these conditions as there exists a variance in when these symptoms arise after radiation. However, we present key epidemiological data delineating vulnerable cancer populations for each pain syndrome along with the available evidence for the management for each specific condition. | ||
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Chronic pain | |
| 650 | 4 | |a Multidisciplinary pain management | |
| 650 | 4 | |a Radiotherapy | |
| 700 | 1 | |a Lachman, Laura |4 aut | |
| 700 | 1 | |a Hanania, Alex |4 aut | |
| 700 | 1 | |a Marathe, Anuj |4 aut | |
| 700 | 1 | |a Singh, Mani |4 aut | |
| 700 | 1 | |a Zacharias, Nicholas |4 aut | |
| 700 | 1 | |a Orhurhu, Vwaire |4 aut | |
| 700 | 1 | |a Gulati, Amitabh |4 aut | |
| 700 | 1 | |a Abd-Elsayed, Alaa |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Springer Healthcare, 1984 |g 38(2021), 3 vom: 11. Feb., Seite 1425-1446 |w (DE-627)168085585 |w (DE-600)632651-1 |w (DE-576)482252200 |x 0741-238X |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2021 |g number:3 |g day:11 |g month:02 |g pages:1425-1446 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s12325-021-01640-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 936 | b | k | |a 44.40$jPharmazie$jPharmazeutika |q VZ |0 106423304 |0 (DE-625)106423304 |
| 951 | |a AR | ||
| 952 | |d 38 |j 2021 |e 3 |b 11 |c 02 |h 1425-1446 | ||